Explore a video, podcast, and interactive infographic to examine underlying type 2 inflammation and the enhanced disease burden in patients with CRSwNP and coexisting asthma, to understand key factors that may predict polyp recurrence, and to explore the value of systematic symptom assessment.
Experience this engaging presentation by Professors Martin Metz, Elena Netchiporouk, and Jason Hawkes to explore emerging therapies for chronic spontaneous urticaria.
Drs. Stephen I. Rennard and Igor Barjaktarevic discuss the diverse clinical aspects of COPD, emphasizing the role of inflammation and the importance of recognizing the heterogeneity of COPD.

Join experts Henrik Watz and Mona Bafadhel for an educational symposium exploring the role of type 2 cytokines in COPD and delve into the link between underlying drivers of COPD with type 2 inflammation and cumulative patient burden.

Join experts Henrik Watz, Mona Bafadhel, and Alberto Papi for an educational symposium on the link between underlying drivers of COPD with type 2 inflammation and cumulative patient burden, exploring the role of type 2 cytokines, and current and emerging therapies.

In this video soundbite from the EAACI 2025 symposium, Dr. Zuzana Diamant explains pathophysiological mechanisms underlying asthma and CRSwNP, and how type 2 inflammatory cytokines drive airway remodelling in patients with severe asthma. Additionally, patients with co-existing asthma and CRSwNP have a higher type 2 inflammatory burden than patients with asthma alone.

In this video from EADV 2025, Dr. Hawkes reviews the pathophysioogy of CSU with a focus on the role of type 2 inflammation
Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.
Type 2 inflammation contributes to many dermatologic diseases, which may lead to potentially life-changing burdens and challenges to patients and caregivers. By uncovering the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP, we can move forward in our understanding of each disease. Join global experts for an educational symposium on March 8th that will uncover the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP and explore questions driving current research in each disease.
Professors Netchiporouk and Hawkes discuss the clinical features and pathophysiology of CSU, at EADV 2025.
Understand the pathophysiology and clinical relevance of mucus plugs in COPD that ultimately contribute to worse outcomes for patients.